REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Heterocyclic Carbon Compounds Containing A Hetero Ring Having Chalcogen (i.e., O,s,se Or Te) Or Nitrogen As The Only Ring Hetero Atoms Doai > Hetero Ring Is Six-membered Consisting Of Three Nitrogens And Three Carbon Atoms > Asymmetrical (e.g., 1,2,4-triazine, Etc.) > Polycyclo Ring System Having The Hetero Ring As One Of The Cyclos Polycyclo Ring System Having The Hetero Ring As One Of The CyclosPolycyclo Ring System Having The Hetero Ring As One Of The Cyclos patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.01/25/07 - 20070021425 - Reverse-turn mimetics and method relating thereto Conformationally constrained compounds that mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins are disclosed. Such reverse-turn mimetic structures have utility over a wide range of fields, including use as diagnostic and therapeutic agents. Libraries containing the reverse-turn mimetic structures of this invention are also disclosed ... 01/18/07 - 20070015760 - Intermediates useful in preparing certain pyrrolotriazine compounds and process for making such intermediates The invention relates to 2,4-dichloropyrrolo[1,2-f][1,2,4]triazines, which are intermediates useful in preparing at least one 2,4-disubstituted pyrrolotriazine compound, and at least one method for making such intermediates. ... 01/04/07 - 20070004734 - Intermediates useful in preparing certain pyrrolotriazine compounds and process for making such intermediates Described herein is at least one pyrrolo[1,2-f][1,2,4]triazine-2,4(1H,3H)-dione, which is an intermediates useful in preparing 2,4-disubstituted pyrrolotriazine compounds, and at least one method for making such intermediate. ... 01/04/07 - 20070004733 - Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith The invention relates to at least one pyrrolotriazine derivative, at least one pharmaceutical composition comprising at least one pyrrolotriazine derivative, and at least one method of using at least one pyrrolotriazine derivative to treat at least one kinase associated condition. ... 01/04/07 - 20070004732 - Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith The invention relates to at least one pyrrolotriazine derivative, at least one pharmaceutical composition comprising at least one pyrrolotriazine derivative, and at least one method of using at least one pyrrolotriazine derivative to treat at least one kinase associated condition. ... 01/04/07 - 20070004731 - Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith The invention relates to at least one pyrrolotriazine derivative, at least one pharmaceutical composition comprising at least one pyrrolotriazine derivative, and at least one method of using at least one pyrrolotriazine derivative to treat at least one kinase associated condition. ... 12/28/06 - 20060293326 - 2-heteroaryl-imidazotriazinones and their use in the treatment of inflammatory or immune diseases The invention relates to 2-Heteroaryl-imidazotriazinones, processes for their preparation and their use in medicaments, esp. for the treatment and/or prophylaxis of inflammatory processes and/or immune diseases. The present invention relates to compounds of the general formula (I) in which R1 denotes 5- to 10-membered heteroaryl, which is optionally substituted by ... 12/21/06 - 20060287322 - Bicyclic heterocycles as cannabinoind-1 receptor modulators including all prodrugs, solvates, pharmaceutically acceptable salts and stereoisomers, wherein B, R1, R2, R3 and x are described herein. ... 11/23/06 - 20060264438 - Pyrrolotriazine compounds as kinase inhibitors and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through ... 10/19/06 - 20060235020 - Process for preparing salts of 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-n-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide and novel stable forms produced therein Processes are provided for selectively preparing novel stable crystalline salt forms, selectively and consistently, namely, preparing Form N-1 of the methanesulfonic acid salt, and Form N-1 and Form N-4 of the hydrochloric acid salt of the p38 kinase inhibitor 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide. The processes preferably employ solvent systems including formic acid/acetone and ... 10/19/06 - 20060235019 - Substituted quinazolinone compounds A variety of low molecular weight, guanidino-containing molecules capable of acting as MC4-R agonists are provided. The compounds are useful in treating MC4-R mediated diseases. The compounds have the structure of Formulas (IA), (IB), or (IC): where the values of the variable are defined herein. ... 09/28/06 - 20060217382 - Imidazotriazine compounds wherein all variables are as defined herein, pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents. ... 09/21/06 - 20060211696 - Imidazo[1,2-b]pyridazine compound Wherein R1 denotes a hydrogen atom, a C1-6 alkyl group, a C1-6 alkoxy group and the like; R2 denotes a halogen atom, a cyano group, a nitro group, a C1-10 alkyl group, a C2-10 alkenyl group, C2-10 alkynyl group and the like; R3 denotes a C6-14 aromatic hydrocarbon cyclic group ... 09/21/06 - 20060211695 - Fused heterocyclic kinase inhibitors including pharmaceutically acceptable salts thereof. The compounds of the invention are useful as protein kinase inhibitors and therefore are useful for treating cancer and other protein kinase mediated diseases. ... 08/24/06 - 20060189615 - 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors The 2-phenyl-substituted imidazotriazinones having short, unbranched alkyl radicals in the 9-position are prepared from the corresponding 2-phenyl-imidazotriazinones by chlorosulphonation and subsequent reaction with the amines. The compounds inhibit cGMP-metabolizing phosphodiesterases and are suitable for use as active compounds in pharmaceuticals, for the treatment of cardiovascular and cerebrovascular disorders and/or disorders ... 07/27/06 - 20060166993 - Substituted imidazotriazines The invention relates to new substituted imidazotriazines, processes for their preparation and their use for the production of medicaments for the treatment and/or prophylaxis of cancer and neurodegenerative disorders, in particular of Parkinson's disease and of schizophrenia. ... 07/27/06 - 20060166992 - Heterocyclically substituted imidazotriazines The invention relates to new heterocyclically substituted imidazotriazines, processes for their preparation and their use for the production of medicaments for the treatment and/or prophylaxis of cancer and neurodegenerative disorders, in particular of Parkinson's disease and of schizophrenia. ... 07/20/06 - 20060160811 - Aryl-condensed 3-arylpridine compounds and use thereof for controlling pathogenic fungi R3 is hydrogen, C1-C6-alkyl, C1-C6-haloalkyl or C3-C6-cycloalkyl which is optionally mono- or polysubstituted by alkyl and/or halogen; and the agriculturally acceptable salts of compounds I, plant protection agents, containing at least one compound of general formula I and/or one agriculturally-acceptable salt of I and at least one liquid or solid ... 07/20/06 - 20060160810 - 2-alkoxyphenyl substituted imidazotriazinones The 2-phenyl-substituted imidazotriazinones having short unbranched alkyl radicals in the 9-position are prepared from the corresponding 2-phenyl-imidazotriazinones by chlorosulphonation and subsequent reaction with the amines. The compounds inhibit cGMP-metabolising phosphodiesterases and are suitable for use as active compounds in pharmaceuticals, for treating cardiovascular and cerebrovascular disorders and/or disorders of the ... 07/06/06 - 20060148801 - Anti-tumor compounds wherein A, D, Q, T, U, V, W, X, Y, Z, R1, and ---- are as defined herein. This invention also relates to a method of inhibiting tubulin polymerization, or treating cancer or an angiogenesis-related disorder with one of these compounds. ... 06/15/06 - 20060128709 - Pyrrolotriazine inhibitors of kinases and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1, PDGFR, HER-1, HER-2, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways ... 06/15/06 - 20060128708 - Antagonizing an adenosine a2a receptor to ameliorate one or more components of addictive behavior This invention provides a method of mitigating/ameliorating one or more components of addictive behavior associated with chronic consumption of a substance of abuse, or withdrawal therefrom. The method typically involves administering to a subject in need thereof an adenosine A2A receptor antagonist in an amount sufficient to ameliorate said one ... 06/15/06 - 20060128707 - Imidazotriazinone derivatives as pde 7 (phosphodiesterase 7) inhibitors The present invention provides the compounds inhibiting PDE 7 selectively, and therefore, enhances cellular cAMP level. Consequently, the compound is useful for treating various kinds of disease such as allergic disease, inflammatory disease or immunologic disease. The compound is imidazotirazinone compound represented by the following formula (IA) or (IB): especially, ... 05/25/06 - 20060111354 - Medicaments containing vardenafil hydrochloride trihydrate The invention relates to a method for producing medicaments that contain vardenafil hydrochloride, essentially as trihydrate in solid form, and to medicaments that can be obtained according to this method ... 04/27/06 - 20060089358 - Pyrrolotriazine compounds and pharmaceutically acceptable salts thereof. The compounds of the invention inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth ... 04/20/06 - 20060084650 - Kinase inhibitors wherein the variables are as defined herein. ... 03/23/06 - 20060063766 - Use of aryl- and heteroaryl-substituted tetrahydroisoquinolines to block reuptake of norepinephrine, dopamine, and serotonin with R1, R2, R3, R4, R5, R6, R7, R8, and R14 defined herein. ... 03/16/06 - 20060058304 - Azaindole kinase inhibitors and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through ... 03/16/06 - 20060058303 - Imidazo-triazine derivatives as ligands for gaba receptors A class of imidazo[1,2b][1,2,4]triazine derivatives, substituted at the 7-position by an optionally substituted five-membered or six-membered heteroaromatic ring, being selective ligands for GABAA receptors, in particular having good affinity for the α2 and/or α3 and/or α5 subunit thereof, are accordingly of benefit in the treatment and/or prevention of adverse conditions ... 02/23/06 - 20060040944 - 5-aza-7-deazapurine derivatives for treating flaviviridae This invention is directed to a method for treating a host, especially a human, infected with hepatitis C, flavivirus and/or pestivirus, comprising administering to that host an effective amount of an anti-flavivirus or anti-pestivirus, biologically active compound has a 5-aza-7-deazapurine moiety. The 5-aza-7-deazapurine moiety may be substituted or unsubstituted, and ... 02/23/06 - 20060040943 - 3-furanyl analogs of toxoflavine as kinase inhibitors the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein m represents an integer being 0 or 1; n represents an integer being 0, 1 or 2; R1 represents C1-4alkyl, C1-4alkyl substituted with pyridinyl, phenyl, piperidinyl or piperidinyl substituted with C1-4alkyloxycarbonyl; R2 represents hydrogen or ... 02/23/06 - 20060040942 - 5-ethylimidarotriazones The invention relates to novel 5-ethyl-imidazotriazinones, processes for their preparation and their use in medicaments, esp. for the treatment and/or prophylaxis of inflammatory processes and/or immune diseases. ... 02/23/06 - 20060040941 - 7-aminoimidazotriazones The invention relates to novel 7-amino-imidazotriazinones, processes for their preparation and their use in medicaments, esp. for the treatment and/or prophylaxis of inflammatory processes and/or immune diseases. ... 02/23/06 - 20060040940 - Imidazopyridines pyrimidines and triazines for enhancing cognition as gaba-a-alphas 5 receoptor subtype ligands The present invention provides a pharmaceutical composition providing a compound of formula I or a pharmaceutically acceptable salt thereof in a pharmaceutically acceptable excipient: (I), in which: X and Y independently represent CH or N, with the proviso that if X is CH then Y is also CH; R1 represents ... 01/26/06 - 20060019957 - Imidazotriazines as protein kinase inhibitors and pharmaceutically acceptable salts thereof, wherein Q1 and R1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of various diseases and conditions that respond to treatment by inhibition of tyrosine kinases. ... 01/19/06 - 20060014745 - Pyrrolotriazine compounds and pharmaceutically acceptable salts thereof. The compounds of the invention inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth ... 01/19/06 - 20060014744 - Midazopyrazinones and imidazotriazinones derivates as gaba-a receptor anxiolytic The present invention discloses a compound of formula I, or a pharmaceutically acceptable salt thereof: (I) wherein —U—V— represents —CH═CH—, or —CH2—CH2—, —N═CH— or —CH═N—; X1 represents hydrogen, halogen, C1-6 alkyl, trifluoromethyl or C1-6 alkoxy; X2 represents hydrogen or halogen; Y represents a chemical bond, an oxygen atom, or a ... 01/12/06 - 20060009454 - Pyrrolotriazine kinase inhibitors and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through ... 01/05/06 - 20060004007 - Pyrrolotriazine inhibitors of kinases and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1, PDGFR, HER-1, HER-2, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways ... 01/05/06 - 20060004006 - Pyrrolotriazine kinase inhibitors including pharmaceutically acceptable salts thereof. The compounds of the invention are useful as protein kinase inhibitors and therefore are useful for treating cancer and other protein kinase mediated diseases. ... 12/29/05 - 20050288290 - Fused heterocyclic kinase inhibitors including pharmaceutically acceptable salts thereof. The compounds of the invention are useful as protein kinase inhibitors and therefore are useful for treating cancer and other protein kinase mediated diseases. ... 12/29/05 - 20050288289 - Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors The present invention is directed to intermediates that are useful for preparing pyrrolotriazines, and processes for preparing such intermediates. ... 12/15/05 - 20050277643 - Bicycloheteroarylamine compounds as ion channel ligands and uses thereof The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, traumatic injury, and others. ... 12/08/05 - 20050272732 - 5-ethyl-imidazo (5,1-f) (1,2,4,) triazin-4 (3h)-ones as phosphodiesterase inhibitors The invention relates to novel 5-ethyl-imidazotriazinones, processes for their preparation and their use in medicaments, esp. for the treatment and/or prophylaxis of inflammatory processes and/or immune diseases. ... 12/01/05 - 20050267112 - Novel imidazotriazinones and the use thereof a method for the production and the pharmaceutical use thereof are disclosed. ... 10/20/05 - 20050234060 - Pyrrolotriazine kinase inhibitors and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through ... 10/13/05 - 20050227985 - Folate mimetics and folate-receptor binding conjugates thereof A cell population expressing folate receptors is selectively targeted with a folate mimetic. The folate mimetic is conjugated to a diagnostic or therapeutic agent to enable selective delivery of the agent to the targeted cell population. ... 10/06/05 - 20050222153 - C-6 modified indazolylpyrrolotriazines and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through ... 09/22/05 - 20050209235 - C-5 modified indazolylpyrrolotriazines and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through ... 09/08/05 - 20050197339 - Di-substituted pyrrolotrizine compounds and pharmaceutically acceptable salts thereof. The compounds of the invention inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents for the treatment of cancer and other diseases. ... 09/01/05 - 20050192278 - Azabicyclic heterocycles as cannabinoid receptor modulators including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R1, R2, R3, and R4 are described herein. ... 08/18/05 - 20050182058 - Pyrrolotriazine compounds as kinase inhibitors and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through ... 08/11/05 - 20050176712 - Integrin expression inhibitor wherein in the formula, B means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated; K means a single bond, —CH═CH— or —(CR4bR5b)mb— (wherein R4b and R5b are the same as or different ... 07/28/05 - 20050165023 - Imidazo-triazine derivatives as ligands for gaba receptors A class of 7-phenylimidazo[1,2-b][1,2,4]triazine derivatives, substituted at the meta position of the phenyl ring by an optionally substituted aryl or heteroaryl group which is directly attached or bridged by an oxygen atom or a —NH— linkage, and substituted on the phenyl ring by one or two further substituents as defined ... 07/14/05 - 20050153966 - Kinase inhibitors The invention relates to compounds of the following formula that may be used to inhibits kinases, as well as compositions of matter and kits comprising these compounds. The present invention also relates to methods for inhibiting kinases, as well as treatment methods using compounds according to the present invention. ... 06/09/05 - 20050124621 - Novel inhibitors of kinases and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through ... 06/09/05 - 20050124620 - Pharmaceutical compounds in which U, T, V and W are each a nitrogen atom or carbon atom. When U, T, V or W is a carbon atom, it may be substituted. The compounds are inhibitors of p38 MAP kinase and are useful for treating inflammatory diseases such as arthritis. An example of ... ### FreshPatents.com Support |